MK-1462
Total Payments
$1.9M
Transactions
29
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $599,184 | 13 | 0 |
| 2018 | $1.3M | 16 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 29 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Two-Part, Double-blind, Multiple-dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1462 in Overweight,Obese Subjects | Merck Sharp & Dohme Corporation | $1.9M | 0 |
Top Doctors Receiving Payments for MK-1462
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lincoln, NE | $1.9M | 29 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 0
- Transactions 29
About MK-1462
MK-1462 is a drug associated with $1.9M in payments to 0 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2019. In 2019, $599,184 was paid across 13 transactions to 0 doctors.
The most common payment nature for MK-1462 is "Unspecified" ($1.9M, 100.0% of total).
MK-1462 is associated with 1 research study, including "A Two-Part, Double-blind, Multiple-dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1462 in Overweight,Obese Subjects" ($1.9M).